<a class="ci-mono font-sans text-ink no-underline hover:text-accent" href="/gene/BRCA1">BRCA1 Mutation

Predictive

Supports Sensitivity Response

accepted

EID12763

In the breast carcinoma cohort of the phase II TAPUR trial (NCT02693535), patients with BRCA1/2 alterations treated with olaparib (26 evaluable) had 1 CR (BRCA2 loss), 11 PR (BRCA1 n=5, BRCA2 n=4, BRC… (full text at CIViC)

PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC

Castration-Resistant Prostate Carcinoma5

BRCA1 Mutation

Fallopian Tube Carcinoma1

Predictive

Supports Sensitivity Response

accepted

EID11203

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

Fallopian Tube Carcinoma1
BRCA1 Mutation OR BRCA2 Mutation	Niraparib	Predictive	A	Supports Sensitivity Response	4	submitted	EID11305 In a randomized, double-blind, phase 3 trial, 553 patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with predominantly high-grade serous histologic features were enroll… (full text at CIViC) PMID 27717299 · Mirza et al., 2016 · Open in CIViC	civic

BRCA1 Mutation OR BRCA2 Mutation

Predictive

Supports Sensitivity Response

submitted

EID11305

In a randomized, double-blind, phase 3 trial, 553 patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with predominantly high-grade serous histologic features were enroll… (full text at CIViC)

PMID 27717299 · Mirza et al., 2016 · Open in CIViC

Lung Carcinoma1
BRCA1 Mutation OR BRCA2 Mutation	Olaparib	Predictive	B	Supports Sensitivity Response	2	accepted	EID12765 In the lung carcinoma cohort of the phase II TAPUR trial (NCT02693535), CRs were observed in 2/25 evaluable patients, both with BRCA2 alterations, with DOR of 33 weeks (SCLC, n=1) and 148 weeks (NSCLC… (full text at CIViC) PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC	civic

Lung Carcinoma1

BRCA1 Mutation OR BRCA2 Mutation

Predictive

Supports Sensitivity Response

accepted

EID12765

In the lung carcinoma cohort of the phase II TAPUR trial (NCT02693535), CRs were observed in 2/25 evaluable patients, both with BRCA2 alterations, with DOR of 33 weeks (SCLC, n=1) and 148 weeks (NSCLC… (full text at CIViC)

PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC

Malignant Biliary Tract Neoplasm1

Malignant Biliary Tract Neoplasm1
BRCA1 Mutation OR BRCA2 Mutation	Olaparib	Predictive	B	Supports Sensitivity Response	4	accepted	EID12764 In the biliary tract carcinoma cohort of the phase II TAPUR trial (NCT02693535), patients with BRCA1/2 alterations treated with olaparib (18 evaluable) had 2 PR (BRCA1 loss n = 1, BRCA2 mutation n = 1… (full text at CIViC) PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC	civic

BRCA1 Mutation OR BRCA2 Mutation

Predictive

Supports Sensitivity Response

accepted

EID12764

In the biliary tract carcinoma cohort of the phase II TAPUR trial (NCT02693535), patients with BRCA1/2 alterations treated with olaparib (18 evaluable) had 2 PR (BRCA1 loss n = 1, BRCA2 mutation n = 1… (full text at CIViC)

PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC

Malignant Breast Neoplasm1

Malignant Breast Neoplasm1
BRCA1 Mutation	Olaparib	Predictive	B	Supports Sensitivity Response	3	submitted	EID9019 The non-randomized, sequential phase II ICEBERG trial evaluated the efficacy and safety of olaparib monotherapy in 54 patients (2 cohorts of 27 patients, treated with 400mg or 100 mg twice daily) with… (full text at CIViC) PMID 20609467 · Tutt et al., 2010 · Open in CIViC	civic

BRCA1 Mutation

Predictive

Supports Sensitivity Response

submitted

EID9019

The non-randomized, sequential phase II ICEBERG trial evaluated the efficacy and safety of olaparib monotherapy in 54 patients (2 cohorts of 27 patients, treated with 400mg or 100 mg twice daily) with… (full text at CIViC)

PMID 20609467 · Tutt et al., 2010 · Open in CIViC

Malignant Neoplasm1
BRCA1 Mutation	Olaparib	Predictive	B	Supports Sensitivity Response	4	accepted	EID1370 In this phase 1 trial, 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only … (full text at CIViC) PMID 19553641 · Fong et al., 2009 · Open in CIViC	civic

Malignant Neoplasm1

BRCA1 Mutation

Predictive

Supports Sensitivity Response

accepted

EID1370

In this phase 1 trial, 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only … (full text at CIViC)

PMID 19553641 · Fong et al., 2009 · Open in CIViC

Malignant Ovarian Neoplasm10

Malignant Ovarian Neoplasm10
BRCA1 Mutation	(prognostic)	Prognostic	B	Supports Better Outcome	3	accepted	EID1675 664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo. Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and … (full text at CIViC) PMID 26740259 · Harter et al., 2016 · Open in CIViC	civic
BRCA1 Mutation	Olaparib	Predictive	A	Supports Sensitivity Response	5	accepted	EID7274 In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were rando… (full text at CIViC) PMID 30345884 · Moore et al., 2018 · Open in CIViC	civic
BRCA1 Mutation	Olaparib	Predictive	A	Supports Sensitivity Response	1	accepted	EID7275 In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were rando… (full text at CIViC) PMID 30345884 · Moore et al., 2018 · Open in CIViC	civic
BRCA1 Mutation	Olaparib	Predictive	A	Supports Sensitivity Response	5	rejected	EID7277 In phase 3 trial for patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had coplete or partial response after platinum-based chemotherapy were treated with ola… (full text at CIViC) PMID 30345884 · Moore et al., 2018 · Open in CIViC	civic
BRCA1 Mutation	Olaparib	Predictive	B	Supports Sensitivity Response	3	accepted	EID1772 In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations. Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective r… (full text at CIViC) PMID 21862407 · Gelmon et al., 2011 · Open in CIViC	civic
BRCA1 Mutation	Cediranib + OlaparibCombination	Predictive	B	Supports Sensitivity Response	3	accepted	EID1677 46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy. Median PFS was increased in combination therapy (… (full text at CIViC) PMID 25218906 · Liu et al., 2014 · Open in CIViC	civic
BRCA1 Mutation	Rucaparib	Predictive	A	Supports Sensitivity Response	5	accepted	EID11136 Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or B… (full text at CIViC) PMID 28882436 · Oza et al., 2017 · Open in CIViC	civic
BRCA1 Mutation	Rucaparib	Predictive	A	Supports Sensitivity Response	5	accepted	EID11138 Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or B… (full text at CIViC) PMID 28882436 · Oza et al., 2017 · Open in CIViC	civic
BRCA1 Mutation	Rucaparib	Predictive	B	Supports Sensitivity Response	3	accepted	EID1897 A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC	civic
BRCA1 Mutation	Rucaparib	Predictive	B	Supports Sensitivity Response	3	accepted	EID6341 A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC	civic

BRCA1 Mutation

(prognostic)

Prognostic

Supports Better Outcome

accepted

EID1675

664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo. Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and … (full text at CIViC)

PMID 26740259 · Harter et al., 2016 · Open in CIViC

BRCA1 Mutation

Predictive

Supports Sensitivity Response

accepted

EID7274

In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were rando… (full text at CIViC)

PMID 30345884 · Moore et al., 2018 · Open in CIViC

BRCA1 Mutation

Predictive

Supports Sensitivity Response

accepted

EID7275

PMID 30345884 · Moore et al., 2018 · Open in CIViC

BRCA1 Mutation

Predictive

Supports Sensitivity Response

rejected

EID7277

In phase 3 trial for patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had coplete or partial response after platinum-based chemotherapy were treated with ola… (full text at CIViC)

PMID 30345884 · Moore et al., 2018 · Open in CIViC

BRCA1 Mutation

Predictive

Supports Sensitivity Response

accepted

EID1772

In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations. Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective r… (full text at CIViC)

PMID 21862407 · Gelmon et al., 2011 · Open in CIViC

BRCA1 Mutation

Cediranib + OlaparibCombination

Predictive

Supports Sensitivity Response

accepted

EID1677

46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy. Median PFS was increased in combination therapy (… (full text at CIViC)

PMID 25218906 · Liu et al., 2014 · Open in CIViC

BRCA1 Mutation

Predictive

Supports Sensitivity Response

accepted

EID11136

Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or B… (full text at CIViC)

PMID 28882436 · Oza et al., 2017 · Open in CIViC

BRCA1 Mutation

Predictive

Supports Sensitivity Response

accepted

EID11138

PMID 28882436 · Oza et al., 2017 · Open in CIViC

BRCA1 Mutation

Predictive

Supports Sensitivity Response

accepted

EID1897

A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC)

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

BRCA1 Mutation

Predictive

Supports Sensitivity Response

accepted

EID6341

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

Malignant Pancreatic Neoplasm6

Malignant Pancreatic Neoplasm6
BRCA1 Mutation	Cisplatin + OxaliplatinSubstitutes	Predictive	B	Supports Sensitivity Response	4	accepted	EID5915 Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=2… (full text at CIViC) PMID 25072261 · Golan et al., 2014 · Open in CIViC	civic
BRCA1 Mutation	Olaparib	Predictive	B	Supports Sensitivity Response	3	accepted	EID5914 Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Five (21.7%) patients had a BRCA1 mutation. All but one had received prior gemcitabine, and 65% had … (full text at CIViC) PMID 25366685 · Kaufman et al., 2015 · Open in CIViC	civic
BRCA1 Mutation	Rucaparib	Predictive	B	Does Not Support Sensitivity Response	2	submitted	EID9291 For this single-arm phase II trial, patients with locally advanced or metastatic pancreatic cancer (neuroendocrine excluded); and had a confirmed pathogenic or likely pathogenic germline (g) or somati… (full text at CIViC) PMID 33970687 · Reiss et al., 2021 · Open in CIViC	civic
BRCA1 Mutation	Rucaparib	Predictive	C	Does Not Support Sensitivity Response	3	submitted	EID7435 In a phase 2 trial, patients with advanced pancreatic cancer harboring germline or somatic BRCA1/2 mutation were treated with PARP inhibitor Rucaparib. In this trial, none of four patients with germli… (full text at CIViC) PMID 30051098 · Shroff et al., 2018 · Open in CIViC	civic
BRCA1 Mutation	Veliparib	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID5934 Veliparib 400mg BID was administered to patients with germline BRCA1/2-mutated pancreatic cancer. Sixteen patients were enrolled. All except two (12.5%) had previously been treated with platinum thera… (full text at CIViC) PMID 29223478 · Lowery et al., 2018 · Open in CIViC	civic
BRCA1 Mutation	Cisplatin + Gemcitabine + VeliparibCombination	Predictive	B	Supports Sensitivity Response	3	accepted	EID5932 In Phase I study for pancreatic cancer patients GEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of 77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-p… (full text at CIViC) PMID 29338080 · O'Reilly et al., 2018 · Open in CIViC	civic

BRCA1 Mutation

Cisplatin + OxaliplatinSubstitutes

Predictive

Supports Sensitivity Response

accepted

EID5915

Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=2… (full text at CIViC)

PMID 25072261 · Golan et al., 2014 · Open in CIViC

BRCA1 Mutation

Predictive

Supports Sensitivity Response

accepted

EID5914

Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Five (21.7%) patients had a BRCA1 mutation. All but one had received prior gemcitabine, and 65% had … (full text at CIViC)

PMID 25366685 · Kaufman et al., 2015 · Open in CIViC

BRCA1 Mutation

Predictive

Does Not Support Sensitivity Response

submitted

EID9291

For this single-arm phase II trial, patients with locally advanced or metastatic pancreatic cancer (neuroendocrine excluded); and had a confirmed pathogenic or likely pathogenic germline (g) or somati… (full text at CIViC)

PMID 33970687 · Reiss et al., 2021 · Open in CIViC

BRCA1 Mutation

Predictive

Does Not Support Sensitivity Response

submitted

EID7435

In a phase 2 trial, patients with advanced pancreatic cancer harboring germline or somatic BRCA1/2 mutation were treated with PARP inhibitor Rucaparib. In this trial, none of four patients with germli… (full text at CIViC)

PMID 30051098 · Shroff et al., 2018 · Open in CIViC

BRCA1 Mutation

Veliparib

Predictive

Does Not Support Sensitivity Response

accepted

EID5934

Veliparib 400mg BID was administered to patients with germline BRCA1/2-mutated pancreatic cancer. Sixteen patients were enrolled. All except two (12.5%) had previously been treated with platinum thera… (full text at CIViC)

PMID 29223478 · Lowery et al., 2018 · Open in CIViC

BRCA1 Mutation

Cisplatin + Gemcitabine + VeliparibCombination

Predictive

Supports Sensitivity Response

accepted

EID5932

In Phase I study for pancreatic cancer patients GEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of 77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-p… (full text at CIViC)

PMID 29338080 · O'Reilly et al., 2018 · Open in CIViC

Malignant Prostate Neoplasm6

Malignant Prostate Neoplasm6
BRCA1 Mutation	Olaparib	Predictive	A	Supports Sensitivity Response	2	submitted	EID12943 In the post hoc exploratory BRCA1-only subgroup (n = 13; olaparib, n = 8; control, n = 5) of the phase III randomized open-label PROfound trial (NCT02987543), olaparib monotherapy supported Sensitivit… (full text at CIViC) PMID 37963304 · Mateo et al., 2024 · Open in CIViC	civic
BRCA1 Mutation	Olaparib	Predictive	B	Supports Sensitivity Response	3	submitted	EID7459 In a retrospective study, 23 consecutive patients with prostate cancer harboring germline BRCA1/2 or ATM mutations were treated with olaparib were reviewed. This study included 2 patients with BRCA1 m… (full text at CIViC) PMID 30797618 · Marshall et al., 2019 · Open in CIViC	civic
BRCA1 Mutation	Olaparib	Predictive	B	Supports Sensitivity Response	4	submitted	EID7470 In a phase 2 trial, patients with metastatic castration-resistant prostate cancer harboring DNA damage repair (DDR) gene aberrations were treated with olaparib. In gene testing, samples from tumor tis… (full text at CIViC) Open in CIViC	civic
BRCA1 Mutation AND BRCA2 Mutation	Olaparib	Predictive	A	Supports Sensitivity Response	4	submitted	EID12941 In the BRCA‑altered cohort (n = 160; BRCA1/2 alterations) of the global, randomized, open‑label phase III PROfound trial (NCT02987543) in metastatic castration‑resistant prostate cancer (mCRPC), patie… (full text at CIViC) PMID 37963304 · Mateo et al., 2024 · Open in CIViC	civic
BRCA1 Mutation AND BRCA2 Mutation	Rucaparib	Predictive	A	Supports Sensitivity Response	4	rejected	EID11245 In an open-label, phase 2 study, 115 male patients with castration-resistant prostate cancer and a BRCA1/2 alteration with or without measurable disease were enrolled to receive rucaparib 600 mg twice… (full text at CIViC) PMID 32795228 · Abida et al., 2020 · Open in CIViC	civic
BRCA1 Mutation OR BRCA2 Mutation	Olaparib	Predictive	B	Supports Sensitivity Response	3	accepted	EID11666 A clinical study was conducted in 30 patients with Metastatic Prostate Cancer harboring BRCA1/2 mutations treated with olaparib. A disease control rate of 69% (95% CI, 51-81) and an objective response… (full text at CIViC) PMID 36753688 · Yang et al., 2023 · Open in CIViC	civic

BRCA1 Mutation

Predictive

Supports Sensitivity Response

submitted

EID12943

In the post hoc exploratory BRCA1-only subgroup (n = 13; olaparib, n = 8; control, n = 5) of the phase III randomized open-label PROfound trial (NCT02987543), olaparib monotherapy supported Sensitivit… (full text at CIViC)

PMID 37963304 · Mateo et al., 2024 · Open in CIViC

BRCA1 Mutation

Predictive

Supports Sensitivity Response

submitted

EID7459

In a retrospective study, 23 consecutive patients with prostate cancer harboring germline BRCA1/2 or ATM mutations were treated with olaparib were reviewed. This study included 2 patients with BRCA1 m… (full text at CIViC)

PMID 30797618 · Marshall et al., 2019 · Open in CIViC

BRCA1 Mutation

Predictive

Supports Sensitivity Response

submitted

EID7470

In a phase 2 trial, patients with metastatic castration-resistant prostate cancer harboring DNA damage repair (DDR) gene aberrations were treated with olaparib. In gene testing, samples from tumor tis… (full text at CIViC)

Open in CIViC

BRCA1 Mutation AND BRCA2 Mutation

Predictive

Supports Sensitivity Response

submitted

EID12941

In the BRCA‑altered cohort (n = 160; BRCA1/2 alterations) of the global, randomized, open‑label phase III PROfound trial (NCT02987543) in metastatic castration‑resistant prostate cancer (mCRPC), patie… (full text at CIViC)

PMID 37963304 · Mateo et al., 2024 · Open in CIViC

BRCA1 Mutation AND BRCA2 Mutation

Predictive

Supports Sensitivity Response

rejected

EID11245

In an open-label, phase 2 study, 115 male patients with castration-resistant prostate cancer and a BRCA1/2 alteration with or without measurable disease were enrolled to receive rucaparib 600 mg twice… (full text at CIViC)

PMID 32795228 · Abida et al., 2020 · Open in CIViC

BRCA1 Mutation OR BRCA2 Mutation

Predictive

Supports Sensitivity Response

accepted

EID11666

A clinical study was conducted in 30 patients with Metastatic Prostate Cancer harboring BRCA1/2 mutations treated with olaparib. A disease control rate of 69% (95% CI, 51-81) and an objective response… (full text at CIViC)

PMID 36753688 · Yang et al., 2023 · Open in CIViC

Malignant Uterine Neoplasm1

Malignant Uterine Neoplasm1
BRCA1 Mutation OR BRCA2 Mutation	Olaparib	Predictive	B	Supports Sensitivity Response	2	accepted	EID12766 In the uterine carcinoma cohort of the phase II TAPUR trial (NCT02693535), PRs were observed in 3 of 15 evaluable patients with BRCA1 (n = 2) or BRCA2 (n = 1) alterations, with response durations of 8… (full text at CIViC) PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC	civic

BRCA1 Mutation OR BRCA2 Mutation

Predictive

Supports Sensitivity Response

accepted

EID12766

In the uterine carcinoma cohort of the phase II TAPUR trial (NCT02693535), PRs were observed in 3 of 15 evaluable patients with BRCA1 (n = 2) or BRCA2 (n = 1) alterations, with response durations of 8… (full text at CIViC)

PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC

Ovarian Carcinoma4
BRCA1 Mutation	(prognostic)	Prognostic	B	Supports Better Outcome	3	accepted	EID464 In patients with invasive epithelial ovarian cancer, those with mutations in BRCA1 had better five-year overall survival. PMID 22274685 · Bolton et al., 2012 · Open in CIViC	civic
BRCA1 Mutation OR BRCA2 Mutation	Niraparib	Predictive	A	Supports Sensitivity Response	4	accepted	EID11243 In a randomized, double-blind, phase 3 trial, 553 patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with predominantly high-grade serous histologic features were enroll… (full text at CIViC) PMID 27717299 · Mirza et al., 2016 · Open in CIViC	civic
BRCA1 Mutation	Platinum Compound	Predictive	B	Supports Sensitivity Response	3	accepted	EID1529 In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0… (full text at CIViC) PMID 24240112 · Pennington et al., 2014 · Open in CIViC	civic
BRCA1 Mutation	Platinum Compound	Predictive	B	Supports Sensitivity Response	3	accepted	EID1531 In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.… (full text at CIViC) PMID 24240112 · Pennington et al., 2014 · Open in CIViC	civic

Ovarian Carcinoma4

BRCA1 Mutation

(prognostic)

Prognostic

Supports Better Outcome

accepted

EID464

In patients with invasive epithelial ovarian cancer, those with mutations in BRCA1 had better five-year overall survival.

PMID 22274685 · Bolton et al., 2012 · Open in CIViC

BRCA1 Mutation OR BRCA2 Mutation

Predictive

Supports Sensitivity Response

accepted

EID11243

PMID 27717299 · Mirza et al., 2016 · Open in CIViC

BRCA1 Mutation

Platinum Compound

Predictive

Supports Sensitivity Response

accepted

EID1529

In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0… (full text at CIViC)

PMID 24240112 · Pennington et al., 2014 · Open in CIViC

BRCA1 Mutation

Platinum Compound

Predictive

Supports Sensitivity Response

accepted

EID1531

In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.… (full text at CIViC)

PMID 24240112 · Pennington et al., 2014 · Open in CIViC

Ovarian Serous Adenocarcinoma1

Ovarian Serous Adenocarcinoma1
BRCA1 Mutation	Olaparib	Predictive	B	Supports Sensitivity Response	4	submitted	EID6333 In patients with platinum-sensitive, recurrent serous ovarian cancer with BRCA mutation, median PFS was significantly longer in patients that received olaparib as compared to placebo (11.2 vs. 4.3 mon… (full text at CIViC) PMID 24882434 · Ledermann et al., 2014 · Open in CIViC	civic

BRCA1 Mutation

Predictive

Supports Sensitivity Response

submitted

EID6333

In patients with platinum-sensitive, recurrent serous ovarian cancer with BRCA mutation, median PFS was significantly longer in patients that received olaparib as compared to placebo (11.2 vs. 4.3 mon… (full text at CIViC)

PMID 24882434 · Ledermann et al., 2014 · Open in CIViC

Pancreatic Adenocarcinoma1

Pancreatic Adenocarcinoma1
BRCA1 Mutation OR BRCA2 Mutation OR PALB2 Mutation	Rucaparib	Predictive	B	Supports Sensitivity Response	3	submitted	EID11317 In this phase II study, 46 patients were enrolled (42 were evaluable; 27 gBRCA2, seven gBRCA1, six gPALB2, and two sBRCA2) and their chemotherapy was discontinued; patients then received rucaparib 600… (full text at CIViC) PMID 33970687 · Reiss et al., 2021 · Open in CIViC	civic

BRCA1 Mutation OR BRCA2 Mutation OR PALB2 Mutation

Predictive

Supports Sensitivity Response

submitted

EID11317

In this phase II study, 46 patients were enrolled (42 were evaluable; 27 gBRCA2, seven gBRCA1, six gPALB2, and two sBRCA2) and their chemotherapy was discontinued; patients then received rucaparib 600… (full text at CIViC)

PMID 33970687 · Reiss et al., 2021 · Open in CIViC

Solid Neoplasm1
BRCA1 Mutation OR BRCA2 Mutation	Olaparib	Predictive	B	Supports Sensitivity Response	2	accepted	EID12767 Across all TAPUR cohorts combined (n = 116 evaluable; BC n = 26, BTC n = 18, LC n = 25, UC n = 15, and additional solid tumors with low accural n = 32), patients with advanced solid tumors harboring B… (full text at CIViC) PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC	civic

Solid Neoplasm1

BRCA1 Mutation OR BRCA2 Mutation

Predictive

Supports Sensitivity Response

accepted

EID12767

Across all TAPUR cohorts combined (n = 116 evaluable; BC n = 26, BTC n = 18, LC n = 25, UC n = 15, and additional solid tumors with low accural n = 32), patients with advanced solid tumors harboring B… (full text at CIViC)

PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC

Triple-Negative Breast Carcinoma2

Triple-Negative Breast Carcinoma2
BRCA1 Mutation	Carboplatin + CisplatinSubstitutes	Predictive	B	Supports Sensitivity Response	3	accepted	EID1684 In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.0… (full text at CIViC) PMID 25847936 · Isakoff et al., 2015 · Open in CIViC	civic
BRCA1 Mutation	Olaparib	Predictive	B	Supports Resistance	3	accepted	EID1775 In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative. Regardless of BRCA status, none showed objective response when treated with olaparib. PMID 21862407 · Gelmon et al., 2011 · Open in CIViC	civic

BRCA1 Mutation

Carboplatin + CisplatinSubstitutes

Predictive

Supports Sensitivity Response

accepted

EID1684

In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.0… (full text at CIViC)

PMID 25847936 · Isakoff et al., 2015 · Open in CIViC

BRCA1 Mutation

Predictive

Supports Resistance

accepted

EID1775

In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative. Regardless of BRCA status, none showed objective response when treated with olaparib.

PMID 21862407 · Gelmon et al., 2011 · Open in CIViC

Fallopian Tube, Ovarian Cancer, And Peritoneal Serous Carcinoma1unmapped disease
BRCA1 Mutation OR BRCA2 Mutation	Rucaparib	Predictive	A	Supports Sensitivity Response	4	submitted	EID11246 In an integrated analysis of Study 10 (NCT01482715) and ARIEL2 (NCT01891344) trials, 106 patients with either germline or somatic BRCA1 or BRCA2 who received a starting dose of oral rucaparib 600mg tw… (full text at CIViC) PMID 28882436 · Oza et al., 2017 · Open in CIViC	civic

Fallopian Tube, Ovarian Cancer, And Peritoneal Serous Carcinoma1unmapped disease

BRCA1 Mutation OR BRCA2 Mutation

Predictive

Supports Sensitivity Response

submitted

EID11246

In an integrated analysis of Study 10 (NCT01482715) and ARIEL2 (NCT01891344) trials, 106 patients with either germline or somatic BRCA1 or BRCA2 who received a starting dose of oral rucaparib 600mg tw… (full text at CIViC)

PMID 28882436 · Oza et al., 2017 · Open in CIViC

HER2 Negative Breast Cancer1unmapped disease
BRCA1 Mutation	Olaparib	Predictive	B	Supports Sensitivity Response	4	accepted	EID5830 Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2–negative metastatic breast cancer. 205 patients we… (full text at CIViC) PMID 28792849 · 2017 · Open in CIViC	civic

HER2 Negative Breast Cancer1unmapped disease

BRCA1 Mutation

Predictive

Supports Sensitivity Response

accepted

EID5830

Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2–negative metastatic breast cancer. 205 patients we… (full text at CIViC)

PMID 28792849 · 2017 · Open in CIViC

High Grade Ovarian Serous Carcinoma3unmapped disease
BRCA1 Mutation	Niraparib	Predictive	B	Supports Sensitivity Response	5	submitted	EID13120 ENGOT-OV16/NOVA was a phase 3, placebo-controlled maintenance trial conducted in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer, the majority of whom… (full text at CIViC) PMID 27717299 · Mirza et al., 2016 · Open in CIViC	civic
BRCA1 Mutation	Niraparib	Predictive	B	Supports Sensitivity Response	4	submitted	EID13122 PRIMA/ENGOT-OV26/GOG-3012 was a phase 3 placebo-controlled maintenance trial that included 733 patients with newly diagnosed, advanced FIGO stage III–IV high-grade serous or endometrioid malignancies … (full text at CIViC) PMID 31562799 · González-Martín et al., 2019 · Open in CIViC	civic
BRCA1 Mutation	Olaparib	Predictive	B	Supports Sensitivity Response	5	submitted	EID13118 SOLO2/ENGOT-Ov21 was a randomized phase 3 maintenance study enrolling 295 women with recurrent, platinum-sensitive high-grade serous or endometrioid malignancies of the ovary, fallopian tube, or perit… (full text at CIViC) PMID 28754483 · Pujade-Lauraine et al., 2017 · Open in CIViC	civic

High Grade Ovarian Serous Carcinoma3unmapped disease

BRCA1 Mutation

Predictive

Supports Sensitivity Response

submitted

EID13120

ENGOT-OV16/NOVA was a phase 3, placebo-controlled maintenance trial conducted in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer, the majority of whom… (full text at CIViC)

PMID 27717299 · Mirza et al., 2016 · Open in CIViC

BRCA1 Mutation

Predictive

Supports Sensitivity Response

submitted

EID13122

PRIMA/ENGOT-OV26/GOG-3012 was a phase 3 placebo-controlled maintenance trial that included 733 patients with newly diagnosed, advanced FIGO stage III–IV high-grade serous or endometrioid malignancies … (full text at CIViC)

PMID 31562799 · González-Martín et al., 2019 · Open in CIViC

BRCA1 Mutation

Predictive

Supports Sensitivity Response

submitted

EID13118

SOLO2/ENGOT-Ov21 was a randomized phase 3 maintenance study enrolling 295 women with recurrent, platinum-sensitive high-grade serous or endometrioid malignancies of the ovary, fallopian tube, or perit… (full text at CIViC)

PMID 28754483 · Pujade-Lauraine et al., 2017 · Open in CIViC

Peritoneal Carcinoma1unmapped disease
BRCA1 Mutation OR BRCA2 Mutation	Niraparib	Predictive	A	Supports Sensitivity Response	4	submitted	EID11304 In a randomized, double-blind, phase 3 trial, 553 patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with predominantly high-grade serous histologic features were enroll… (full text at CIViC) PMID 27717299 · Mirza et al., 2016 · Open in CIViC	civic

Peritoneal Carcinoma1unmapped disease

BRCA1 Mutation OR BRCA2 Mutation

Predictive

Supports Sensitivity Response

submitted

EID11304

PMID 27717299 · Mirza et al., 2016 · Open in CIViC